Zhu Delin, Stevenson Freda K
Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, UK.
Curr Opin Mol Ther. 2002 Feb;4(1):41-8.
The ability of DNA vaccination to induce effective immune responses has been shown in a range of preclinical disease models. However, the potency of DNA vaccines must be further improved for their use in patients. DNA fusion vaccine strategies, whereby target antigens are genetically linked to immuno-enhancing molecules, are currently being explored. The ease of DNA manipulation has allowed incorporation of a wide variety of molecules able to promote antigen uptake, processing and presentation by professional antigen-presenting cells, to provide critical CD4 T-cell help and to activate more effective immune effector pathways. These strategies are particularly important for cancer vaccines to increase their immunogenicity and to overcome tolerance.
DNA疫苗诱导有效免疫反应的能力已在一系列临床前疾病模型中得到证实。然而,DNA疫苗的效力必须进一步提高才能用于患者。目前正在探索DNA融合疫苗策略,即将靶抗原与免疫增强分子进行基因连接。DNA操作的简便性使得能够纳入多种分子,这些分子能够促进专职抗原呈递细胞对抗原的摄取、加工和呈递,提供关键的CD4 T细胞辅助,并激活更有效的免疫效应途径。这些策略对于癌症疫苗提高其免疫原性和克服耐受性尤为重要。